Browsing by Author "Şekeroǧlu, R."

Now showing 1 - 2 of 2

The Comparative Effects of Pentoxifylline and Ursodeoxycholic Acid on Il-1β, Il-6, Il-8 and Tnf-Α Levels in Nonalcoholic Fatty Liver
(2003) Tuncer, I.; Uygan, I.; Dülger, H.; Türkdoǧan, K.; Şekeroǧlu, R.; Kösem, M.
Objective: To investigate the comparative effects of the pentoxifylline (PTX) and ursodeoxycholic acid (UDCA) on IL-1β, IL-6, IL-8 and TNF-α in non-alcoholic fatty liver (NAFL) cases. Method: Twenty-eight cases diagnosed to have NAFL were included in our study. The cases were divided into 3 groups. 20 mg/kg/day PTX was given to the subjects in group A (6 male, 4 female), 15 mg/kg/day UDCA was given to the subjects in group B (5 males, 5 females) for 6 months. The cases in group C (5 male, 3 female) were followed as control group. The biochemical values and cytokine levels of the cases were evaluated before and at the end of the sixth month of the treatment. Results: When compared with the serum cytokine levels before and after the treatment, IL-8 and TNF-α levels were found to be significantly decreased both in group A and group B (p< 0.05), whereas there was no statistically significant change in IL-1β and IL-6 levels (p > 0.05). Conclusion: While PTX and UDCA significantly decreased the serum IL-8 and TNF-α levels in NAFL, their effects on IL-1β and IL-6 were not significant.
Comparison of Serum Cytokeratin-18, Cea and Ca 19-9 Levels in Esophageal and Gastric Cancers
(2004) Tuncer, I.; Dülger, H.; Uygan, I.; Öztürk, M.; Kotan, Ç.; Şekeroǧlu, R.
The aim of this study was to determine clinical value of alone and combined use of serum cytokeratin (CK)-18, carcinoembryonic antigen (CEA) and CA 19-9 in esophageal squamous cell carcinoma and gastric adenocarcinoma. Serum tumor markers were measured in 60 patients who had esophageal squamous cell carcinoma or gastric adenocarcinoma. Thirty healthy subjects served as controls. In patients with gastric adecarcinoma serum CK-18 levels were significantly increased compared to both esophageal squamus cell carcinoma and control groups (p<0.01, p<0,05 respectively). But there was no significant difference in CK-18 levels between esophageal squamous cell carcinoma patients and healthy subjects (p>0.05). On the other hand, serum CEA and CA 19-9 levels did not differ between groups (p>0.05). The sensitivity of serum CK-18, CEA and CA19- 9 in esophageal squamous cell carcinoma were 53%, 70% and 66%, respectively. For gastric adenocarcinoma, the sensitivity of each tumor marker was similar 70%, 70% and 70%, respectively. CK-18/CA19-9 combination in the esophageal (83%) and gastric carcinomas (93%) were found to be more sensitive than other tumor markers when these markers were evaluated in combination. CEA exhibited the highest sensitivity for esophageal squamous cell carcinoma compared to CK-18, and CA19-9. However, the sensitivity of all tumor markers in gastric adenocarcinoma were similar. The combination of CK-18 and CA19-9 could increase the diagnostic sensitivity in esophageal and gastric carcinomas.